# Platinum Nephrotoxicity: Tubules and Electrolytes

A toxicity decision should consider curative potential, alternatives, and reversibility. Avoid treating all platinum agents as clinically interchangeable.

![Infographic: Platinum Nephrotoxicity: Tubules and Electrolytes](https://urinenephrology.org/visual-reference/images/mastery-platinum.png?v=20261003c)

## Separate the platinum agents

Cisplatin commonly raises concerns about tubular injury and magnesium wasting; carboplatin dosing is linked to target exposure and a kidney-function estimate. Do not use a cisplatin toxicity rule as a carboplatin dosing formula, or assume the agents are interchangeable alternatives for cancer efficacy.

## Identify susceptibility

Baseline CKD, dehydration, interacting drugs, cumulative exposure, and treatment intensity can modify risk.

## Check more than creatinine

Magnesium, potassium, phosphate, volume status, and symptoms can reveal tubular dysfunction before or beyond a major filtration change.

## Verify the renal estimate before the cycle

Review recent kidney trajectory and whether the dosing protocol requires measured or estimated GFR. A stable creatinine equation can mislead during AKI or marked muscle loss. Coordinate the prescribed target exposure, hydration, magnesium support, and dose decision with oncology and pharmacy.

## Follow delayed effects

Electrolyte wasting may persist after exposure. Repeated replacement without investigating the ongoing renal loss can miss the mechanism.

## Preserve cancer and kidney goals

A toxicity decision should consider curative potential, alternatives, and reversibility. Avoid treating all platinum agents as clinically interchangeable.

## Source lessons

- [platinum nephrotoxicity](https://urinenephrology.org/mastery/onconephrology/platinum-nephrotoxicity.html)

Read alongside the full lessons; the findings and decisions shown here require the stated clinical context.